| NCT ID | NCT06619288 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Affiliated Hospital of Nantong University |
| Condition | HIV Infection |
| Study Type | OBSERVATIONAL |
| Enrollment | 630 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 630 participants in total. It began in 2024-07-01 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥18 years) diagnosed with HIV/AIDS, ART-naive, from July 2024 to June 2025 (prospective) or January 2020 to June 2023 (retrospective). 2. Eligible for ART initiation with B/F/TAF or previously treated with TDF+3TC+EFV or DTG/3TC. 3. Willing to adhere to study procedures and follow-up visits or have complete electronic health records (EHRs). Exclusion Criteria: 1. Severe renal impairment (creatinine clearance \< 50 mL/min). 2. Hepatitis B co-infection or severe hepatic impairment (Child-Pugh Class C). 3. Active tuberculosis (TB).
Contact & Investigator
Gang Qin, MD, PhD
STUDY CHAIR
Affiliated Hospital of Nantong University
Frequently Asked Questions
Who can join the NCT06619288 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06619288 currently recruiting?
Yes, NCT06619288 is actively recruiting participants. Contact the research team at tonygqin@ntu.edu.cn for enrollment information.
Where is the NCT06619288 trial being conducted?
This trial is being conducted at Nantong, China.
Who is sponsoring the NCT06619288 clinical trial?
NCT06619288 is sponsored by Affiliated Hospital of Nantong University. The principal investigator is Gang Qin, MD, PhD at Affiliated Hospital of Nantong University. The trial plans to enroll 630 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.